Patient Sex Age at Diagnosis Histologic Subtype Treatment Received Adverse Effects of Treatment Genetic Findings Clinical Response Follow-up from Diagnosis (years)
A M 9 Spitzoid WLE, nivolumab Chills BAP1 retained CR 0.12
B M 12 Spitzoid WLE, nivolumab Grade 3 lichenoid eruption BRAF neg, VUS in POLE CR 3.01
C F 10 Spitzoid WLE, nivolumab Mild dermatitis that improved with steroids BAP1 retained, positive for SOX-10 and S-100, neg for p16, CD34, desmin and SALL-4, Ki67 20-50% CR 2.05
D
M
8
Severely atypical spindle cell melanocytic tumor
WLE, nivolumab
No autoimmune effects
Not tested
CR
0.98
E
M
9
Spitzoid
WLE, nivolumab, left neck dissection, radiation
Hypothyroidism, hypereosinophilia
Negative Invitae Multi-Cancer Panel
CR
3.40
F
M
13
Unspecified
WLE, Nivolumab, complete neck dissection levels I-IV, radiation
No autoimmune effects
Class 2B Castle Diagnostics Gene Expression Profile
CR
1.24
G
M
20
Superficial spreading
WLE, right neck dissection, nivolumab,superficial parotidectomy at progression
Colitis with negative colonoscopy that improved with steroids
Neg for BRAF, KIT, IDH2, MAP2K1, PDGFRA, EGFR, MET, PIK3CA, IDH1, KRAS, NRAS, VUS in AIP and EGF
Initially progressed Now CR
2.10